new listings
First in new biologics class to treat psoriasis
The first in a new class of biologic medicine that acts to interrupt the inflammatory cycle and help clear the skin of patients with moderate-to-severe psoriasis has been added to the PBS from September 1, 2015.
GBMA welcomes infliximab biosimilar listing
The Generic and Biosimilar Medicines Association has welcomed the approval of biosimilar infliximab, Inflectra. Inflectra is the first biosimilar infliximab to be approved in Australia, providing an alternative, affordable treatment …
Macular oedema treatment to be available on PBS
A government subsidy for a biologic to treat vision impairment caused by macular oedema in patients with diabetes or retinal vein occlusion (branch or central) will be available from 1 July.
Melanoma treatment to be PBS-listed
MSD has welcomed the Federal Government’s announcement that patients with the most deadly form of skin cancer – advanced melanoma – will be able to access the company’s anti-PD1 immunotherapy …
New hepatitis C treatment approved
The TGA has approved a new hepatitis C treatment, Gilead Sciences, Australia New Zealand, today announced.
MA expresses PBS Budget fears
Medicines Australia has expressed concerns about the proposed cuts to the PBS in tomorrow’s Budget. Health Minister, Sussan Ley’s announcement of the listing of new medicines and vaccines on the …
Macular disease treatment PBS listed
Macular Disease Foundation Australia today applauded the Federal Government’s decision to place the registered drug ranibizumab (Lucentis) on the PBS, enabling patients affordable access to this sight saving treatment for …
GMiA welcomes ‘a’ flagging of biosimilars
The Generic Medicines Industry Association has welcomed the PBAC’s decision to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the PBS. Basaglar is the first biosimilar …